Karyopharm Therapeutics Inc. short interest in 2026
In 2026, Karyopharm Therapeutics Inc.'s disclosed short interest ran from 8.58% of shares outstanding on 15 Jan 2026 to 34.68% on 15 Sep 2026, a change of +26.10 percentage points. The year's high was 43.27% on 31 Aug 2026 and its low 8.58% on 15 Jan 2026, averaging 26.20% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.13 days on 15 Jul 2026. Full history: Karyopharm Therapeutics Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 8.58% (15 Jan 2026)
- End of year
- 34.68% (15 Sep 2026)
- Change
- +26.10 pp
- High
- 43.27% (31 Aug 2026)
- Low
- 8.58% (15 Jan 2026)
- Average
- 26.20%
- Highest days to cover
- 17.13 (15 Jul 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 8.58% | 1.48 | results (8-K) |
| 30 Jan 2026 | 15.59% | 3.95 | |
| 13 Feb 2026 | 13.45% | 2.89 | results (8-K), 10-K filed |
| 27 Feb 2026 | 16.20% | 5.76 | |
| 13 Mar 2026 | 19.58% | 5.03 | |
| 31 Mar 2026 | 29.75% | 2.29 | |
| 15 Apr 2026 | 31.17% | 8.99 | |
| 30 Apr 2026 | 28.86% | 14.50 | |
| 15 May 2026 | 23.28% | 11.52 | 10-Q filed, results (8-K) |
| 29 May 2026 | 23.60% | 11.90 | |
| 15 Jun 2026 | 24.64% | 16.79 | |
| 30 Jun 2026 | 29.05% | 9.12 | |
| 15 Jul 2026 | 27.85% | 17.13 | |
| 31 Jul 2026 | 33.34% | 2.67 | |
| 14 Aug 2026 | 42.51% | 4.46 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 43.27% | 9.35 | |
| 15 Sep 2026 | 34.68% | 5.01 |
See also: Karyopharm Therapeutics Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.